Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects

• Status: Terminated
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to assess the effects of rifampin on the pharmacokinetics of dapagliflozin

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Bristol-Myers Squibb
• Treatments: Dapagliflozin; Rifampin

Criteria

Inclusion Criteria:

• Healthy subjects

• Body Mass Index (BMI) of 18 to 32 inclusive

• Women who are not of childbearing potential and men, ages 18 to 45

Exclusion Criteria:

• Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, electrocardiogram (ECG) or clinical laboratory determinations

• Glucosuria

• Abnormal liver function tests